InBodyLtd (A041830) Stock Overview
Provides body composition analysis solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for A041830 from our risk checks.
A041830 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
InBody Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩31,750.00 |
| 52 Week High | ₩32,050.00 |
| 52 Week Low | ₩20,700.00 |
| Beta | 0.51 |
| 1 Month Change | 17.16% |
| 3 Month Change | 35.97% |
| 1 Year Change | 29.33% |
| 3 Year Change | 63.66% |
| 5 Year Change | 97.21% |
| Change since IPO | 1,330.82% |
Recent News & Updates
Recent updates
Insufficient Growth At InBody Co.,Ltd (KOSDAQ:041830) Hampers Share Price
Oct 02
There's No Escaping InBody Co.,Ltd's (KOSDAQ:041830) Muted Earnings
Nov 12Be Wary Of InBodyLtd (KOSDAQ:041830) And Its Returns On Capital
Aug 12InBodyLtd (KOSDAQ:041830) Could Be Struggling To Allocate Capital
Apr 12Why Dividend Hunters Love InBody Co.,Ltd (KOSDAQ:041830)
Mar 25Can InBody Co.,Ltd (KOSDAQ:041830) Performance Keep Up Given Its Mixed Bag Of Fundamentals?
Mar 08Do Insiders Own Lots Of Shares In InBody Co.,Ltd (KOSDAQ:041830)?
Feb 18
How Much Did InBodyLtd's(KOSDAQ:041830) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 31Has InBodyLtd (KOSDAQ:041830) Got What It Takes To Become A Multi-Bagger?
Jan 11InBody Co., Ltd. (KOSDAQ:041830) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24Why Dividend Hunters Love InBody Co., Ltd. (KOSDAQ:041830)
Dec 17InBody Co., Ltd.'s (KOSDAQ:041830) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Dec 02Do Institutions Own InBody Co., Ltd. (KOSDAQ:041830) Shares?
Nov 17Shareholder Returns
| A041830 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 14.0% | -0.6% | 4.5% |
| 1Y | 29.3% | -23.7% | 34.3% |
Return vs Industry: A041830 exceeded the KR Medical Equipment industry which returned -22.6% over the past year.
Return vs Market: A041830 underperformed the KR Market which returned 34.8% over the past year.
Price Volatility
| A041830 volatility | |
|---|---|
| A041830 Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 10.4% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A041830 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A041830's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 342 | Ki-Chul Cha | www.inbody.co.kr |
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in bariatric, cardiology, diabetes, frailty and aging, ICU, lymphedema, nephrology, nutrition, oncology, sports medicine, and rehabilitation and physical therapy applications.
InBody Co.,Ltd Fundamentals Summary
| A041830 fundamental statistics | |
|---|---|
| Market cap | ₩387.10b |
| Earnings (TTM) | ₩30.62b |
| Revenue (TTM) | ₩217.55b |
Is A041830 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A041830 income statement (TTM) | |
|---|---|
| Revenue | ₩217.55b |
| Cost of Revenue | ₩48.56b |
| Gross Profit | ₩168.99b |
| Other Expenses | ₩138.36b |
| Earnings | ₩30.62b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.51k |
| Gross Margin | 77.68% |
| Net Profit Margin | 14.08% |
| Debt/Equity Ratio | 0% |
How did A041830 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 08:44 |
| End of Day Share Price | 2025/10/02 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InBody Co.,Ltd is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kathy Park | CGS International |
| null null | DBS Bank Ltd |
| Jaesong Woo | Haitong International Research Limited |